GBT Projected Dividend Yield
Global Blood Therapeutics Inc ( NASDAQ : GBT )Global Blood Therapeutics is a biopharmaceutical company that engaged in the discovery, development and delivery of treatments to underserved patient communities. The U.S. Food and Drug Administration has granted approval for Co.'s Oxbryta® (voxelotor) tablets for the treatment of sickle cell disease (SCD) in adults and children 12 years of age and older. Oxbryta, an oral therapy taken once daily, is the treatment that directly inhibits sickle hemoglobin polymerization, the root cause of SCD. Co. is developing treatments for SCD, including inclacumab, a P-selectin inhibitor used to reduce the incidence of vaso-occlusive crises and hemoglobin polymerization inhibitor, GBT021601, or GBT601. 20 YEAR PERFORMANCE RESULTS |
GBT Dividend History Detail GBT Dividend News GBT Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |